Skip to main content

Advertisement

Table 2 Summary of demographics, glucocorticoid dose, and treatments to reduce bone lossa for patients with or without morphometric vertebral fractures

From: Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy

Parameter Vertebral fractures
Overall Present Absent
N = 576 N = 109 N = 467
Age, years    
 Mean (SD) 59.6 (15.00) 69.7 (10.81) 57.3 (14.88)
 P-valueb   <0.001
BMI, kg/m2    
 Mean (SD) 26.8 (4.83) 26.6 (3.61) 26.9 (5.08)
P-valueb   0.724
Race, n (%)    
 Caucasian 566 (98.3) 109 (100) 457 (97.9)
 Black 3 (0.5) 0 (0.0) 3 (0.6)
 American Indian or Alaska native 5 (0.9) 0 (0.0) 5 (1.1)
 Other 2 (0.3) 0 (0.0) 2 (0.4)
Menopause, n (%)    
 Started 422 (73.3) 104 (95.4) 318 (68.1)
 Started at age ≤40 37 (6.4) 11 (10.1) 26 (5.6)
 Not started 150 (26.0) 4 (3.7) 146 (31.3)
 Unknown 4 (0.7) 1 (0.9) 3 (0.6)
Time since menopause, years    
 Mean (SD) 18.1 (10.66) 22.4 (10.06) 16.7 (10.47)
 P-valueb   <0.001
Height, cm    
 Mean (SD) 158.2 (7.20) 155.9 (7.61) 158.7 (7.00)
 P-valueb   <0.001
Cumulative GC dose, g    
 Mean (SD) 15.5 (18.77) 18.3 (23.00) 14.9 (17.63)
 P-valueb   0.346
Time from the start of GC use, years    
 Mean (SD) 7.4 (6.15) 8.4 (7.60) 7.1 (5.74)
 P-valueb   0.279
Percentage of patients taking calcium and/or vitamin D 49.3 52.3 48.6
 Calcium 45.0 49.5 43.9
 Vitamin D 45.0 51.4 43.5
Percentage of patients taking bisphosphonates 42.7 66.1 37.3
 Alendronate 20.3 32.1 17.6
 Risedronate 16.5 22.9 15.0
 Ibandronate 9.7 19.3 7.5
 Zoledronic acid 1.2 2.8 0.9
Percentage of patients taking other medications    
 Strontium ranelate 2.3 3.7 1.9
 Teriparatide 1.9 6.4 0.9
 Raloxifine 1.2 2.8 0.9
  1. BMI body mass index, GC glucocorticoid, n number of patients, N total number of patients in group, SD standard deviation
  2. aTreatments to reduce bone loss used by ≥1.2 % of the overall population
  3. bP-value is for the difference between the 2 fracture cohorts, calculated using Kruskal-Wallis test